Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,292.00
(
0.66%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
100.06
(
-0.59%
)
Bitcoin
74,019.95
(
0.10%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: floblu14 post# 115954

Sunday, 03/06/2011 6:57:16 PM

Sunday, March 06, 2011 6:57:16 PM

Post# of 257253

…is it correct to say that TEVA could possibly get an injunction which would prevent Sandoz/MNTA launching at risk for generic copaxone?

No, we cannot say that. Teva might be able to get a preliminary injunction to block the launch of generic Copaxone; however, the likelihood of Teva’s getting a PI will be diminished if the Judge believes Teva is unlikely to prevail in the Copaxone trial.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now